Relating to the establishment of a consortium to conduct United States Food and Drug Administration's drug development clinical trials with ibogaine to secure the administration's approval of the medication's use for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy and to the administration of that treatment.
Relating to prohibited retaliation against a physician or health care provider for reporting certain violations or taking certain actions with respect to the provision of health care services; providing a civil remedy.
Relating to a prohibition on governmental contracts with Chinese companies for certain information and communications technology; authorizing a civil penalty; creating a criminal offense.
Relating to the creation of an enhanced license designation for a license to carry a handgun and the locations in which the holder of that enhanced license may carry a handgun.